Wednesday, May 1, 2024
5/1/2024
PROJECT ABSTRACT Cyanobacteria produce secondary metabolites have been well-documented to possess potent and selective anticancer activity, which has resulted in FDA approval of a cyanobacterial antibody-drug-conjugate (ADC) for the treatment of several Hodgkin lymphomas. Even though this highlights the critical role of natural products in the drug discovery, the novelty of structural scaffolds has largely remained steady in the last two decades. Therefore, we aim to design and synthesize a pseudo-natural product library inspired by cyanobacterial metabolites with well-described anti-cancer activity to expand their molecular coverage. Our pseudo-natural product library will develop and describe uncharted chemical space that integrates privileged scaffolds while employing medicinal chemistry approaches, such as combinatorial chemistry and parallel synthesis. We will qualitatively and quantitatively characterize our library using modern computational, machine learning and metabolomic techniques, to compare it with natural products and FDA-approved drugs. The long-term goal of this research is to generate a chemical library rich in natural product scaffolds that are biased towards cancer tissue for drug discovery and development. Our main hypothesis is that our library will contain chemical architectures embedded with biological properties of privileged cyanobacterial structures that describe new chemical space.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
